

David J Farrell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11994878/publications.pdf>

Version: 2024-02-01

146
papers

6,488
citations

50276

46
h-index

82547

72
g-index

146
all docs

146
docs citations

146
times ranked

5246
citing authors

#	ARTICLE	IF	CITATIONS
1	Short-Read Whole-Genome Sequencing for Laboratory-Based Surveillance of <i>Bordetella pertussis</i> . <i>Journal of Clinical Microbiology</i> , 2017, 55, 1446-1453.	3.9	3
2	Prevalence of macrolide–lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents. <i>Journal of Global Antimicrobial Resistance</i> , 2017, 8, 28-32.	2.2	8
3	Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2558-2563.	3.2	13
4	Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5393-5399.	3.2	32
5	In vitro activity of dalbavancin against multidrug-resistant <i>Staphylococcus aureus</i> and streptococci from patients with documented infections in Europe and surrounding regions (2011–2013). <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 495-499.	2.5	16
6	Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011–2014). <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 144-150.	2.5	52
7	Comparison of BD Max StaphSR and BD Max MRSA <i>XT</i> for Screening of <i>Staphylococcus aureus</i> Clinical Isolates Collected from Hospitals in the United States. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1668-1669.	3.9	1
8	Ceftaroline activity tested against viridans group streptococci from US hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 84, 232-235.	1.8	6
9	Results from the Solithromycin International Surveillance Program (2014). <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3662-3668.	3.2	28
10	Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative <i>Staphylococcus</i> causing infection in US hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 85, 80-84.	1.8	19
11	<i>In Vitro</i> Activity of Lefamulin Tested against <i>Streptococcus pneumoniae</i> with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4407-4411.	3.2	38
12	Longitudinal (2001–14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010–13) analysis of oritavancin <i>in vitro</i> potency. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3453-3458.	3.0	71
13	In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 86, 66-69.	1.8	11
14	Activity of Fusidic Acid Tested against <i>Staphylococci</i> Isolated from Patients in U.S. Medical Centers in 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3827-3831.	3.2	22
15	<i>In Vitro</i> Activity of Ceftazidime-Avibactam against Contemporary <i>Pseudomonas aeruginosa</i> Isolates from U.S. Medical Centers by Census Region, 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2537-2541.	3.2	30
16	Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011–2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin. <i>Journal of Chemotherapy</i> , 2016, 28, 83-88.	1.5	9
17	Antimicrobial Activity of Ceftaroline Tested against <i>Staphylococcus aureus</i> from Surgical Skin and Skin Structure Infections in US Medical Centers. <i>Surgical Infections</i> , 2016, 17, 443-447.	1.4	12
18	Oritavancin Activity Tested against Molecularly Characterized <i>Staphylococci</i> and <i>Enterococci</i> Displaying Elevated Linezolid MIC Results. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3817-3820.	3.2	2

#	ARTICLE	IF	CITATIONS
19	<i>In Vitro</i> Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-clAI Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 666-668.	3.2	15
20	Performance of BD Max StaphSR for Screening of Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates among a Contemporary and Diverse Collection from 146 Institutions Located in Nine U.S. Census Regions: Prevalence of <i>mecA</i> Dropout Mutants. <i>Journal of Clinical Microbiology</i> , 2016, 54, 204-207.	3.9	15
21	Genotypic Characterization of Methicillin-Resistant <i>Staphylococcus aureus</i> Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole. <i>Microbial Drug Resistance</i> , 2016, 22, 53-58.	2.0	5
22	Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13): Table 1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 276-278.	3.0	20
23	Ceftaroline Activity against Bacterial Pathogens Frequently Isolated in U.S. Medical Centers: Results from Five Years of the AWARE Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2458-2461.	3.2	27
24	Ceftazidime-Avibactam Activity against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Isolated in U.S. Medical Centers in 2012 and 2013. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3656-3659.	3.2	74
25	Noninvasive <i>Streptococcus pneumoniae</i> Serotypes Recovered from Hospitalized Adult Patients in the United States in 2009 to 2012. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5595-5601.	3.2	24
26	<i>In Vitro</i> Spectrum of Pexiganan Activity When Tested against Pathogens from Diabetic Foot Infections and with Selected Resistance Mechanisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1751-1754.	3.2	59
27	Activity of Debio1452, a FabI Inhibitor with Potent Activity against <i>Staphylococcus aureus</i> and Coagulase-Negative <i>Staphylococcus</i> spp., Including Multidrug-Resistant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2583-2587.	3.2	30
28	<i>In Vitro</i> Activity of RX-P873 against Enterobacteriaceae, <i>Pseudomonas aeruginosa</i> , and <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2280-2285.	3.2	8
29	Detection of a New <i>cfr</i> -Like Gene, <i>cfr</i> (B), in <i>Enterococcus faecium</i> Isolates Recovered from Human Specimens in the United States as Part of the SENTRY Antimicrobial Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6256-6261.	3.2	124
30	Analysis of 5-year trends in daptomycin activity tested against <i>Staphylococcus aureus</i> and enterococci from European and US hospitals (2009-13). <i>Journal of Global Antimicrobial Resistance</i> , 2015, 3, 161-165.	2.2	14
31	Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible <i>Citrobacter</i> spp., <i>Enterobacter</i> spp., <i>Serratia marcescens</i> , and <i>Pseudomonas aeruginosa</i> from United States medical centers (2011-14). <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 389-394.	1.8	25
32	Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 82, 78-84.	1.8	16
33	In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 81, 283-289.	1.8	25
34	Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 53-59.	2.5	75
35	Telavancin <i>In Vitro</i> Activity against a Collection of Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates, Including Resistant Subsets, from the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1811-1814.	3.2	24
36	Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-13). <i>Journal of Global Antimicrobial Resistance</i> , 2015, 3, 36-39.	2.2	3

#	ARTICLE	IF	CITATIONS
37	Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 81, 275-279.	1.8	42
38	Arbekacin Activity against Contemporary Clinical Bacteria Isolated from Patients Hospitalized with Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3263-3270.	3.2	26
39	Activity of ceftaroline and comparator agents tested against <i>Staphylococcus aureus</i> from patients with bloodstream infections in US medical centres (2009-13). <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2053-2056.	3.0	28
40	Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 379-381.	1.8	33
41	Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against <i>Neisseria gonorrhoeae</i> . <i>Journal of Clinical Microbiology</i> , 2015, 53, 3888-3890.	3.9	4
42	Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2727-2730.	3.9	8
43	Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13). <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 498-504.	3.0	32
44	Baseline Activity of Telavancin against Gram-Positive Clinical Isolates Responsible for Documented Infections in U.S. Hospitals (2011-2012) as Determined by the Revised Susceptibility Testing Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 702-706.	3.2	21
45	Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 80, 233-238.	1.8	44
46	Molecular Analysis of Antimicrobial Resistance Mechanisms in <i>Neisseria gonorrhoeae</i> Isolates from Ontario, Canada. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 632-632.	3.2	1
47	Multilocus Sequence Typing of <i>Mycobacterium xenopi</i> . <i>Journal of Clinical Microbiology</i> , 2014, 52, 3973-3977.	3.9	5
48	Oritavancin Activity against <i>Staphylococcus aureus</i> Causing Invasive Infections in U.S. and European Hospitals: a 5-Year International Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2921-2924.	3.2	30
49	Revised Reference Broth Microdilution Method for Testing Telavancin: Effect on MIC Results and Correlation with Other Testing Methodologies. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5547-5551.	3.2	42
50	Decreased Ceftriaxone Susceptibility in Emerging (35B and 6C) and Persisting (19A) <i>Streptococcus pneumoniae</i> Serotypes in the United States, 2011-2012: Ceftaroline Remains Active <i>In Vitro</i> among β -Lactam Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4923-4927.	3.2	19
51	Ceftaroline Activity Tested Against Bacterial Isolates From Pediatric Patients. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 837-842.	2.0	20
52	Antimicrobial Activity of Ceftaroline Tested against Drug-Resistant Subsets of <i>Streptococcus pneumoniae</i> from U.S. Medical Centers. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2468-2471.	3.2	21
53	Ceftobiprole Activity against over 60,000 Clinical Bacterial Pathogens Isolated in Europe, Turkey, and Israel from 2005 to 2010. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3882-3888.	3.2	62
54	Surveillance of antimicrobial resistance in contemporary clinical isolates of <i>Bordetella pertussis</i> in Ontario, Canada. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 82-84.	2.5	8

#	ARTICLE	IF	CITATIONS
55	Activity of ceftobiprole against methicillin-resistant <i>Staphylococcus aureus</i> strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 323-327.	2.5	22
56	Variation in Potency and Spectrum of Tigecycline Activity against Bacterial Strains from U.S. Medical Centers since Its Approval for Clinical Use (2006 to 2012). <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2274-2280.	3.2	41
57	Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 78, 443-448.	1.8	184
58	Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012). <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 78, 449-456.	1.8	19
59	Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1684-1692.	3.2	129
60	Mutation-Driven β -Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible <i>Pseudomonas aeruginosa</i> Isolates from U.S. Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6844-6850.	3.2	118
61	Antimicrobial activity of ceftolozane/tazobactam tested against <i>Pseudomonas aeruginosa</i> and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2713-2722.	3.0	130
62	Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 533-539.	2.5	123
63	Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: Summary of 8 years of a Worldwide Surveillance Programme (2005-2012). <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 465-469.	2.5	76
64	Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). <i>Journal of Infection</i> , 2014, 69, 266-277.	3.3	75
65	Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 328-334.	2.5	194
66	Antimicrobial susceptibility of clinical isolates of anaerobic bacteria in Ontario, 2010-2011. <i>Anaerobe</i> , 2014, 28, 120-125.	2.1	61
67	Linezolid resistance in <i>Enterococcus faecium</i> isolated in Ontario, Canada. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 77, 350-353.	1.8	53
68	Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 75, 86-88.	1.8	15
69	Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012). <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6305-6310.	3.2	177
70	Rifaximin in the Treatment of Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 205-211.	2.2	20
71	AWARE Ceftaroline Surveillance Program (2008-2010): Trends in Resistance Patterns Among <i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> , and <i>Moraxella catarrhalis</i> in the United States. <i>Clinical Infectious Diseases</i> , 2012, 55, S187-S193.	5.8	68
72	Summary of Ceftaroline Activity against Pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2933-2940.	3.2	71

#	ARTICLE	IF	CITATIONS
73	Worldwide Appraisal and Update (2010) of Telavancin Activity Tested against a Collection of Gram-Positive Clinical Pathogens from Five Continents. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3999-4004.	3.2	35
74	Oritavancin Activity against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci with Molecularly Characterized Glycopeptide Resistance Genes Recovered from Bacteremic Patients, 2009-2010. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1639-1642.	3.2	31
75	Activity Analyses of Staphylococcal Isolates From Pediatric, Adult, and Elderly Patients: AWARE Ceftaroline Surveillance Program. <i>Clinical Infectious Diseases</i> , 2012, 55, S181-S186.	5.8	30
76	Ceftaroline Potency Among 9 US Census Regions: Report From the 2010 AWARE Program. <i>Clinical Infectious Diseases</i> , 2012, 55, S194-S205.	5.8	16
77	In Vitro Activity of Ceftaroline Against Multidrug-Resistant <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> : A Review of Published Studies and the AWARE Surveillance Program (2008-2010). <i>Clinical Infectious Diseases</i> , 2012, 55, S206-S214.	5.8	78
78	Molecular Epidemiology of <i>Staphylococcus epidermidis</i> Clinical Isolates from U.S. Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4656-4661.	3.2	75
79	ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries. <i>Journal of Chemotherapy</i> , 2012, 24, 328-337.	1.5	18
80	Characterization of Methicillin-Resistant <i>Staphylococcus aureus</i> Strains Recovered from a Phase IV Clinical Trial for Linezolid versus Vancomycin for Treatment of Nosocomial Pneumonia. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3694-3702.	3.9	34
81	Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009). <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 72, 113-117.	1.8	21
82	Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 321-325.	2.5	12
83	LEADER Surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 74, 54-61.	1.8	45
84	Activity of JNJ-Q2 against <i>Staphylococcus aureus</i> isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 74, 73-74.	1.8	2
85	Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β -Lactamases and Methicillin-Resistant <i>Staphylococcus aureus</i> Carrying Various Staphylococcal Cassette Chromosome <i>mec</i> Types. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4779-4785.	3.2	70
86	Characterization of Global Patterns and the Genetics of Fusidic Acid Resistance. <i>Clinical Infectious Diseases</i> , 2011, 52, S487-S492.	5.8	65
87	Molecular Analysis of Antimicrobial Resistance Mechanisms in <i>Neisseria gonorrhoeae</i> Isolates from Ontario, Canada. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 703-712.	3.2	93
88	Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 39-45.	2.5	36
89	Susceptibility of <i>Klebsiella</i> spp. to colistin and polymyxin B: results from the SENTRY Antimicrobial Surveillance Program (2006-2009). <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 174-175.	2.5	16
90	Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, iii69-iii80.	3.0	43

#	ARTICLE	IF	CITATIONS
91	In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 275-279.	1.8	10
92	Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005–2009). <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 223-227.	1.8	31
93	Update on the telavancin activity tested against European staphylococcal clinical isolates (2009–2010). <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 93-97.	1.8	22
94	Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 sentry antimicrobial surveillance program. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 415-420.	1.8	8
95	LEADER Program Results for 2009: an Activity and Spectrum Analysis of Linezolid Using 6,414 Clinical Isolates from 56 Medical Centers in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3684-3690.	3.2	79
96	JNJ-Q2, a New Fluoroquinolone with Potent In Vitro Activity against Staphylococcus aureus, Including Methicillin- and Fluoroquinolone-Resistant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3631-3634.	3.2	21
97	Investigation of the Potential for Mutational Resistance to XF-73, Retapamulin, Mupirocin, Fusidic Acid, Daptomycin, and Vancomycin in Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates during a 55-Passage Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1177-1181.	3.2	82
98	Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2390-2394.	3.2	112
99	In Vitro Activity and Single-Step Mutational Analysis of Rifamycin SV Tested against Enteropathogens Associated with Traveler's Diarrhea and Clostridium difficile. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 992-996.	3.2	15
100	The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009). <i>Journal of Infection</i> , 2010, 61, 476-483.	3.3	33
101	Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2329-2335.	3.0	126
102	beta-lactamase and antibiotic resistances in a global cross-sectional study of Moraxella catarrhalis from children and adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 91-97.	3.0	38
103	Antimicrobial Susceptibilities of a Worldwide Collection of Stenotrophomonas maltophilia Isolates Tested against Tigecycline and Agents Commonly Used for S. maltophilia Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2735-2737.	3.2	93
104	Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 537-543.	2.5	43
105	In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 531-536.	2.5	42
106	Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008). <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1353-1358.	3.0	89
107	CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 66, 393-401.	1.8	48
108	Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998–2009). <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 68, 334-336.	1.8	54

#	ARTICLE	IF	CITATIONS
109	Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 68, 459-467.	1.8	39
110	Increase in Pneumococcus Macrolide Resistance, United States. <i>Emerging Infectious Diseases</i> , 2009, 15, 1260-1264.	4.3	93
111	Genome-wide dissection of globally emergent multi-drug resistant serotype 19A <i>Streptococcus pneumoniae</i> . <i>BMC Genomics</i> , 2009, 10, 642.	2.8	98
112	Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003-2004). <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 302-308.	1.8	15
113	Linezolid surveillance program results for 2008 (LEADER Program for 2008). <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 65, 392-403.	1.8	76
114	Trends in antibacterial resistance among <i>Streptococcus pneumoniae</i> isolated in the USA: update from PROTEKT US Years 1-4. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2008, 7, 1.	3.8	133
115	Distribution and antibacterial susceptibility of macrolide resistance genotypes in <i>Streptococcus pneumoniae</i> : PROTEKT Year 5 (2003-2004). <i>International Journal of Antimicrobial Agents</i> , 2008, 31, 245-249.	2.5	54
116	Non-susceptibility trends and serotype distributions among <i>Streptococcus pneumoniae</i> from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, ii87-ii95.	3.0	28
117	Telithromycin Resistance in <i>Streptococcus pneumoniae</i> Is Conferred by a Deletion in the Leader Sequence of erm (B) That Increases rRNA Methylation. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 435-440.	3.2	32
118	Antimicrobial Susceptibility of Respiratory Tract Pathogens in Japan During PROTEKT Years 1-5 (1999-2004). <i>Microbial Drug Resistance</i> , 2008, 14, 109-117.	2.0	24
119	Age-related genotypic and phenotypic differences in <i>Moraxella catarrhalis</i> isolates from children and adults presenting with respiratory disease in 2001-2002. <i>Microbiology (United Kingdom)</i> , 2008, 154, 1178-1184.	1.8	41
120	Prevalence and Antibacterial Susceptibility of mef (A)-Positive Macrolide-Resistant <i>Streptococcus pneumoniae</i> over 4 Years (2000 to 2004) of the PROTEKT US Study. <i>Journal of Clinical Microbiology</i> , 2007, 45, 290-293.	3.9	32
121	The Macrolide Resistance Genes <i>erm</i> (B) and <i>mef</i> (E) Are Carried by Tn 2010 in Dual-Gene <i>Streptococcus pneumoniae</i> Isolates Belonging to Clonal Complex CC271. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4184-4186.	3.2	47
122	Increased Antimicrobial Resistance Among Nonvaccine Serotypes of <i>Streptococcus pneumoniae</i> in the Pediatric Population After the Introduction of 7-Valent Pneumococcal Vaccine in the United States. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 123-128.	2.0	207
123	Antibacterial resistance patterns in <i>Streptococcus pneumoniae</i> isolated from elderly patients: PROTEKT years 1-5 (1999-2004). <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 546-550.	2.5	9
124	Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2007, 6, 7.	3.8	15
125	<i>Streptococcus pyogenes</i> Isolates with High-Level Macrolide Resistance and Reduced Susceptibility to Telithromycin Associated with 23S rRNA Mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 817-818.	3.2	17
126	Heterogeneous Macrolide Resistance and Gene Conversion in the Pneumococcus. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 359-361.	3.2	15

#	ARTICLE	IF	CITATIONS
127	Trends in anti-bacterial resistance among <i>Streptococcus pneumoniae</i> isolated in the USA, 2000-2003: PROTEKT US years 1-3. <i>Journal of Infection</i> , 2005, 51, 355-363.	3.3	58
128	Emergence and Spread of <i>Streptococcus pneumoniae</i> with <i>erm</i> (B) and <i>mef</i> (A) Resistance. <i>Emerging Infectious Diseases</i> , 2005, 11, 851-867.	4.3	108
129	The PROTEKT global study (year 4) demonstrates a continued lack of resistance development to telithromycin in <i>Streptococcus pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 795-797.	3.0	12
130	Novel Mechanism of Resistance to Oxazolidinones, Macrolides, and Chloramphenicol in Ribosomal Protein L4 of the Pneumococcus. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3554-3557.	3.2	138
131	Assessment of the efficacy of telithromycin simulating human exposures against <i>S. pneumoniae</i> with ribosomal mutations in a murine pneumonia model. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 530-534.	2.5	6
132	Evaluation of telithromycin against <i>Streptococcus pneumoniae</i> with ribosomal mutations utilizing in vitro time-kill methodology. <i>International Journal of Antimicrobial Agents</i> , 2005, 26, 331-334.	2.5	0
133	Antibacterial susceptibility among <i>Streptococcus pneumoniae</i> isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, i23-i29.	3.0	26
134	Activities of Telithromycin against 13,874 <i>Streptococcus pneumoniae</i> Isolates Collected between 1999 and 2003. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1882-1884.	3.2	46
135	Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among <i>Streptococcus pneumoniae</i> isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, i17-i22.	3.0	50
136	Molecular Epidemiology of Multiresistant <i>Streptococcus pneumoniae</i> with Both <i>erm</i> (B)- and <i>mef</i> (A)-Mediated Macrolide Resistance. <i>Journal of Clinical Microbiology</i> , 2004, 42, 764-768.	3.9	78
137	In Vitro Activities of Telithromycin, Linezolid, and Quinupristin-Dalfopristin against <i>Streptococcus pneumoniae</i> with Macrolide Resistance Due to Ribosomal Mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3169-3171.	3.2	78
138	Prevalence and Molecular Analysis of Macrolide and Fluoroquinolone Resistance among Isolates of <i>Streptococcus pneumoniae</i> Collected during the 2000-2001 PROTEKT US Study. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4980-4987.	3.9	38
139	Molecular Characterization and Antimicrobial Susceptibility of Fluoroquinolone-Resistant or -Susceptible <i>Streptococcus pneumoniae</i> from Hong Kong. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1433-1435.	3.2	26
140	Quinupristin-Dalfopristin Resistance in <i>Streptococcus pneumoniae</i> : Novel L22 Ribosomal Protein Mutation in Two Clinical Isolates from the SENTRY Antimicrobial Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2696-2698.	3.2	27
141	Urinary screening for neisseria gonorrhoeae in asymptomatic individuals from queensland, australia: an evaluation using three nucleic acid amplification methods. <i>Pathology</i> , 2001, 33, 204-205.	0.6	7
142	Evaluation of AMPLICOR <i>Neisseria gonorrhoeae</i> PCR Using <i>cppB</i> Nested PCR and 16S rRNA PCR. <i>Journal of Clinical Microbiology</i> , 1999, 37, 386-390.	3.9	126
143	The Role of <i>Ureaplasma urealyticum</i> in Adverse Pregnancy Outcome. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1997, 37, 45-51.	1.0	24
144	Comparison of PCR/nucleic acid hybridization and EIA for the detection of <i>Chlamydia trachomatis</i> in different populations in a regional centre. <i>Pathology</i> , 1996, 28, 74-79.	0.6	5

#	ARTICLE	IF	CITATIONS
145	Neonatal Infection Due to Haemophilus Influenzae Biotype IV. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1995, 35, 102-103.	1.0	5
146	Ureaplasma Urealyticum Chorioamnionitis. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1994, 34, 477-479.	1.0	11